ContraFect Appoints Michael Messinger as Chief Financial Officer
November 12 2018 - 07:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of protein and
antibody therapeutics for life-threatening, drug-resistant
infectious diseases, today announced the appointment of Michael
Messinger as the Company’s Chief Financial Officer. Mr. Messinger
previously served as the Company’s Senior Vice President of
Finance.
Prior to joining the Company in 2012, Mr. Messinger was Director
of Finance at Lexicon Pharmaceuticals, where he was responsible for
the financial management of Lexicon's partnership with Symphony
Capital, in addition to fiscal coordination and project management
concerning Lexicon's development programs. Before that, Mr.
Messinger was Controller at Coelacanth Corporation. Previously, he
was an auditor at Ernst & Young. Mr. Messinger is a Certified
Public Accountant, and holds a Bachelor of Business Administration
in Accounting from the University of Michigan.
“We are pleased to announce Mike’s promotion to Chief Financial
Officer,” said Steven Gilman, Ph.D., the Company's Chairman and
Chief Executive Officer. “Mike has made critical contributions to
our corporate mission and successfully led our finance and
accounting efforts over the past six years, including playing an
integral role in raising over $100M to fund our important work. We
look forward to his continued contributions to the progress of the
Company.”
“I am honored to take on this new role at ContraFect,” said
Michael Messinger, the Company's Chief Financial Officer. “The
Company is developing an exciting portfolio of lysin and other
therapeutics, and I am pleased to continue working alongside the
rest of the executive team to lead the finance function, build
value for shareholders, and support the advancement of treatments
for patients suffering from life-threatening infectious
diseases.”
About ContraFect:
ContraFect is a biotechnology company focused on discovering and
developing therapeutic protein and antibody products for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin and monoclonal
antibody platforms to target conserved regions of either bacteria
or viruses (regions that are not prone to mutation). ContraFect's
initial product candidates include new agents to treat
antibiotic-resistant infections such as MRSA (Methicillin-resistant
Staph aureus) and influenza. ContraFect’s lead product candidate,
CF-301, is currently in a Phase 2 clinical trial for the treatment
of Staph aureus bacteremia, including endocarditis and is the first
lysin to enter clinical studies in the U.S. ContraFect is
also conducting research focused on the discovery of lysins to
target Gram-negative bacteria.
Forward-Looking
Statements:
This press release contains, and our officers and
representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop protein and antibody therapeutics for
life-threatening, drug-resistant infectious diseases, whether Mr.
Messinger’s contributions were critical to the corporate mission of
the company, whether he played an integral role in raising $100M,
whether he will contribute to the progress of the company, whether
he will continue to work with the executive team to build value for
the shareholders and support the advancement of treatments for
patients suffering from life-threatening infectious diseases,
the Company’s ability to address life threatening infections
using our therapeutic product candidates from our lysin and
monoclonal antibody platforms to target conserved regions of either
bacteria or viruses, whether our initial product candidates can
treat antibiotic-resistant infections such as MRSA and influenza,
and our ability to discover new lysins targeting Gram-negative
bacteria. Forward-looking statements are statements that are not
historical facts, nor assurances of future performance. Instead,
they are based on ContraFect’s current beliefs, expectations and
assumptions regarding the future of its business, future plans,
strategies, projections, anticipated events and trends, the economy
and other future conditions. Because forward-looking statements
relate to the future, they are subject to inherent risks,
uncertainties and changes in circumstances that are difficult to
predict and many of which are beyond ContraFect’s control,
including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Matthew ShinsekiStern Investor RelationsTel: 212-362-1200Email:
matthew@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2023 to Mar 2024